OrPro Therapeutics, Inc. is a preclinical stage biopharmaceutical company currently resident inJlabs San Diego. The firm is organized around development of recombinant thioredoxin for the treatment of cystic fibrosis. There is a critical - and, so far, unmet - need for effective treatment of abnormally viscoelastic mucus that drives chronic infection and inflammation in obstructive pulmonary diseases. Poor airway clearance associated with excess mucin protein disulfide bonding has long been a target for mucolytic therapies, especially in cystic fibrosis (CF). However, current approaches exhibit poor clinical efficacy, and may have off-target toxicity and low tolerability. The companyâs overall goal is to develop a breakthrough class of safe, well tolerated and more effective inhaled nonsystemic drugs based on the thioredoxin active site for the treatment of patients with cystic fibrosis (CF), COPD/emphysema, bronchiectasis, severe asthma, and other serious obstructive pulmonary diseases
